MindWalk Holdings Corp. (NASDAQ: HYFT) Launches ReefIQ™, a Biological Context Layer for AI Drug Discovery

MindWalk Holdings Corp. (NASDAQ: HYFT) has launched ReefIQ™, a new biological context layer aimed at enhancing AI-driven drug discovery and biologics development. ReefIQ™ addresses the challenge of fragmented biological data by transforming it into a governed, queryable format, enabling AI workflows to reason over connected context rather than isolated files. This system, built on MindWalk's proprietary HYFT® technology, is designed to preserve valuable program insights and integrate with AI models like LensAI™ to generate more trustworthy hypotheses and accelerate drug development.

Tags

Business Wire EDGAR eir MindWalk Holdings Corp. Nasdaq SEDAR+ Louie Toma British Columbia Victoria Artificial Intelligence Computational Biology Drug Discovery Life Sciences

Key points

Notable quotes

In life-sciences AI, the durable advantage is not the model a team licenses but the biological context it can reason over. Biology is connected by evolutionary constraint; discovery data arrives fragmented across files and systems, and that gap is where insight is lost. ReefIQ is designed to close it, preserving what every program learns, including the programs that fail, as governed context rather than isolated files. In a regulated setting, that is what makes reasoning trustworthy, and trustworthy is what compounds into the clinic,

— Dr. Jennifer Bath

ReefIQ operationalizes the HYFT information network for drug discovery. HYFT provides the biological representation foundation, representing the complex relationships in biology; ReefIQ links customer data to that foundation and exposes governed context to LensAI and customer-selected agent models operating within agreed governance. The goal is to support retrieval, analysis, and hypothesis generation over connected biological context while preserving provenance, deployment flexibility, and customer-defined controls.

— Dirk Van Hyfte

Structured claims — 42

  1. 1
    Monitor MindWalk's product roadmap and market adoption for ReefIQ™ as a new offering in the AI drug discovery space.
    Entities: MindWalk Holdings Corp., ReefIQ™, HYFT®
  2. 2
    Understand ReefIQ's architectural positioning to assess its integration points and potential impact on existing AI drug discovery pipelines.
    Entities: ReefIQ™
  3. 3
    Evaluate ReefIQ's capability to address data fragmentation, a critical bottleneck in AI drug discovery, for potential competitive advantage.
    Entities: ReefIQ™
  4. 4
    Benchmark this stated industry challenge against other solutions and market analyses to understand the problem ReefIQ™ aims to solve.
  5. 5
    Track ReefIQ's technical implementation details to understand how it achieves data reconnection and harmonization for AI workflows.
    Entities: ReefIQ™
  6. 6
    Investigate the integration mechanism between ReefIQ™ and MindWalk's core biological representation foundation for data consistency and scalability.
    Entities: ReefIQ™, MindWalk Holdings Corp.
  7. 7
    Analyze the breadth of data types ReefIQ™ can integrate to assess its comprehensive utility for diverse drug discovery programs.
    Entities: ReefIQ™
  8. 8
    Track this strategic perspective from MindWalk's CEO as a key driver for their product development and market positioning.
    “In life-sciences AI, the durable advantage is not the model a team licenses but the biological context it can reason over.”
    Entities: Dr. Jennifer Bath
  9. 9
    Evaluate ReefIQ's effectiveness in mitigating insight loss from fragmented data, a critical factor for drug discovery efficiency.
    “ReefIQ is designed to close it, preserving what every program learns, including the programs that fail, as governed context rather than isolated files.”
    Entities: Dr. Jennifer Bath, ReefIQ™
  10. 10
    Assess ReefIQ's ability to capture and retain knowledge from all drug discovery programs, including negative results, which is valuable for future research.
    “ReefIQ is designed to close it, preserving what every program learns, including the programs that fail, as governed context rather than isolated files.”
    Entities: Dr. Jennifer Bath, ReefIQ™
  11. 11
    Consider the regulatory compliance implications of ReefIQ's governed context feature for pharmaceutical development and clinical translation.
    “In a regulated setting, that is what makes reasoning trustworthy, and trustworthy is what compounds into the clinic,”
    Entities: Dr. Jennifer Bath
  12. 12
    Evaluate the interoperability of ReefIQ™ with various AI models, including LensAI™, for enhanced hypothesis generation and analysis.
    Entities: LensAI™, ReefIQ™
  13. 13
    Understand HYFT's foundational role within MindWalk's technology stack to assess the company's core intellectual property.
    Entities: HYFT®, MindWalk Holdings Corp.
  14. 14
    Analyze the comprehensive biological relationships captured by HYFT® to understand its potential for deep biological insights.
    Entities: HYFT®
  15. 15
    Map the architectural relationship between ReefIQ™ and HYFT® to understand the modularity and dependencies within MindWalk's platform.
    Entities: ReefIQ™, HYFT®
  16. 16
    Assess ReefIQ's data harmonization capabilities as a key feature for integrating disparate client datasets.
    Entities: ReefIQ™
  17. 17
    Investigate the data linking process to understand how client-specific data enriches MindWalk's broader biological knowledge graph.
    Entities: ReefIQ™, MindWalk Holdings Corp.
  18. 18
    Evaluate ReefIQ's provenance tracking features for regulatory compliance and reproducibility in drug discovery workflows.
    Entities: ReefIQ™
  19. 19
    Assess the governance and queryability features of ReefIQ™ for secure and controlled access by AI models.
    Entities: ReefIQ™, LensAI™
  20. 20
    Understand LensAI's role as the primary AI reasoning component within MindWalk's platform.
    Entities: LensAI™
  21. 21
    Map the specific applications of LensAI™ leveraging ReefIQ's context to identify key areas of impact in drug discovery.
    Entities: LensAI™, ReefIQ™
  22. 22
    Recognize the diverse types of valuable data generated in drug discovery that ReefIQ™ aims to capture and leverage.
  23. 23
    Assess ReefIQ's knowledge preservation capabilities for long-term value creation and learning within drug discovery pipelines.
    Entities: ReefIQ™
  24. 24
    Monitor the growth and refinement of ReefIQ's knowledge network as a measure of its compounding value and utility.
    Entities: ReefIQ™
  25. 25
    Evaluate the long-term benefits and return on investment from ReefIQ's cumulative knowledge base for future drug discovery initiatives.
    Entities: ReefIQ™
  26. 26
    Understand the conceptual framework behind ReefIQ's design, emphasizing its cumulative and interconnected nature.
    Entities: ReefIQ™
  27. 27
    Track how ReefIQ™ translates the underlying HYFT® technology into practical applications for drug discovery workflows.
    “ReefIQ operationalizes the HYFT information network for drug discovery,”
    Entities: Dirk Van Hyfte, ReefIQ™, HYFT®
  28. 28
    Understand the core function of HYFT® as the biological knowledge base underpinning MindWalk's platform.
    “HYFT provides the biological representation foundation, representing the complex relationships in biology;”
    Entities: Dirk Van Hyfte, HYFT®
  29. 29
    Analyze the data flow and governance mechanisms between customer data, ReefIQ™, HYFT®, and AI models for secure and effective integration.
    “ReefIQ links customer data to that foundation and exposes governed context to LensAI and customer-selected agent models operating within agreed governance.”
    Entities: Dirk Van Hyfte, ReefIQ™, HYFT®, LensAI™
  30. 30
    Evaluate ReefIQ's design objectives to understand its intended impact on drug discovery processes and user control.
    Entities: ReefIQ™

Source

Source
mindwalk-holdings-news-releases
Record title
MindWalk Holdings Corp. (NASDAQ: HYFT) Launches ReefIQ™, a Biological Context Layer for AI Drug Discovery
Author
MindWalk
Published
Jun 10, 2026
URL
https://mindwalkai.com/discovery-resources/news/mindwalk-holdings-corp.-nasdaq-hyft-launches-reefiq-a-biological-context-layer-for-ai-drug-discovery
Manifest ID
1781126217202882780
Significance
high
Sentiment
positive